Searching News Database: EntreMed
HSMN NewsFeed - 6 Nov 2020
Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors
Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors
HSMN NewsFeed - 6 Dec 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
HSMN NewsFeed - 9 Sep 2013
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
HSMN NewsFeed - 18 Jun 2008
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
HSMN NewsFeed - 3 Jan 2008
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
HSMN NewsFeed - 11 Dec 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
HSMN NewsFeed - 5 Sep 2007
NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
HSMN NewsFeed - 4 Jun 2007
EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma
EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma
HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
HSMN NewsFeed - 12 Dec 2006
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
HSMN NewsFeed - 13 Jul 2006
Nascent Pharmaceuticals Adds Joanna Horobin, M.D., to Its Board of Directors
Nascent Pharmaceuticals Adds Joanna Horobin, M.D., to Its Board of Directors
HSMN NewsFeed - 28 Jun 2006
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
EntreMed Granted Orphan Drug Designation for Panzem(R) (2ME2) In Glioblastoma
HSMN NewsFeed - 15 May 2006
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
Additional items found! 49
Members Archive contains
49 additional stories matching:
EntreMed
(Password required)
EntreMed
(Password required)
